Efficacy of a Brown Seaweed Powder for Glycemic Control

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02853916

Enrollment

Registered

2016-08-03

Start date

2016-08-31

Completion date

2017-10-25

Last updated

2017-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Glucose

Brief summary

The objectives of this trial are to confirm efficacy in human of a brown seaweed powder and explore dose-response relationship by comparing two different doses. The primary endpoint is incremental area under the curve (iAUC, mmol\*min/L) for blood glucose.

Interventions

DIETARY_SUPPLEMENT500 mg InSea2®

DIETARY_SUPPLEMENT250 mg InSea2®

DIETARY_SUPPLEMENTPlacebo

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Males and females aged between 18-45 y * Normoglycemic (fasting blood glucose \<5.6 mmol/L) * Body mass index (BMI) 18.5-29.9 kg/m2 * Able to consume bread products

Exclusion criteria

* Fasting blood glucose \> 5.6 mmol/L * Systolic blood pressure \> 140 mmHg and/or diastolic blood pressure \> 90 mmHg * Previous history of cardiovascular disease, diabetes, liver or kidney disease, inflammatory bowel disease, celiac disease, short bowel syndrome, any malabsorptive syndrome, pancreatitis, gallbladder or biliary disease * Presence of a gastrointestinal disorder within the past year * Presence of major gastrointestinal surgeries * Thyroid problems * Smokers * Consuming prescription or non-prescription drug, herbal or nutritional supplements known to affect blood glucose or that could affect the outcome of the study as per investigator's judgement * Women that are currently pregnant or lactating, or not using an appropriate contraception method * Excessive alcohol intake (more than 2 drinks per day or more than 9 drinks per week) * Allergic to shellfish (crab) or molluscs * Weight gain or loss of at least 10lbs in previous three months

Design outcomes

Primary

Measure	Time frame	Description
Incremental area under the curve (iAUC, mmol*min/L) of blood glucose	0, 15, 30, 45, 60, 75, 90, 120, 150, 180 and 210 min	Incremental area under the curve (iAUC, mmol\*min/L)

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026